- Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen ®
- Featured presentation by Dr. Elias Michaelides, Yale School of Medicine
Zug, Switzerland, May 31, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced that it will host a Key Opinion Leader event on Friday, June 16, 2017, at 8 am EDT in New York City. The event will focus on Auris Medical's clinical-stage pipeline and feature a presentation by Elias Michaelides, MD, Associate Professor of Surgery, Otolaryngology and Director of the Hearing and Balance Program at the Yale School of Medicine.
To reserve a seat, please contact Cindy McGee via e-mail at investors@aurismedical.com . A live webcast will be available through the Events and Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com and a replay of the presentation will be available following the event.
Auris Medical's clinical-stage development pipeline includes AM-111 for acute inner ear hearing loss, Keyzilen ® (AM-101) for acute inner ear tinnitus and AM-125 for the intranasal treatment of vertigo. Auris Medical is currently enrolling patients in two Phase 3 clinical trials of AM-111, with top-line results from the HEALOS trial expected in the fall of 2017. Auris Medical is also enrolling patients in the TACTT3 trial of Keyzilen ® (AM-101) and expects to announce top-line results in the first quarter of 2018. In addition, Auris Medical will initiate a Phase 1 trial of AM-125 in 2017.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen ® ; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Forward-looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, prevailing market conditions, whether the Company will consummate the offering of shares and warrants on the expected terms, or at all, the satisfaction of closing conditions related to the offering and risks related to the application of the net proceeds, if any, from the offering. There can be no assurance that the Company will be able to complete the offering at the anticipated size or on the anticipated terms, or at all. In any event, the Company may continue to need additional funding and may be unable to raise capital when needed, which could force the Company to delay, reduce or eliminate its product development programs or commercialization efforts. Other risks and uncertainties relating to the Company's business include the timing and conduct of clinical trials of Auris Medical's product candidates, including the likelihood that the TACTT3 clinical trial with Keyzilen ® will not meet its endpoints, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
Media contact: David Schull, Russo Partners, 1-858-717-2310, david.schull@russopartnersllc.com
